87941-55-7

Basic information

• Product Name: 4-BROMO-1-TRITYL-1H-IMIDAZOLE
• Synonyms: 4-BROMO-1-TRITYL-1H-IMIDAZOLE;4-BROMO-1-TRITYLIMIDAZOLE;4-Bromo-1-trityl-1H-imidazde;4-Bromo-1-[tris(phenyl)methyl]-1H-imidazole;1-Trityl-4-BroMo IMidazole;4-Bromo-1-(triphenylmethyl)-1H-imidazole
• CAS NO: 87941-55-7
• Molecular Formula: C₂₂H₁₇BrN₂
• Molecular Weight: 389.29
• Product Categories: blocks;Bromides;Imidazoles;API intermediates
• Mol File: 87941-55-7.mol

Chemical Properties

• Melting Point: 248-250 °C(Solv: ethanol (64-17-5))
• Boiling Point: 492.5 °C at 760 mmHg
• Flash Point: 251.7 °C
• Appearance: /
• Density: 1.27 g/cm³
• Vapor Pressure: 2.31E-09mmHg at 25°C
• Refractive Index: 1.629
• PKA: 3.60±0.61(Predicted)
• CAS DataBase Reference: 4-BROMO-1-TRITYL-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-1-TRITYL-1H-IMIDAZOLE(87941-55-7)
• EPA Substance Registry System: 4-BROMO-1-TRITYL-1H-IMIDAZOLE(87941-55-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 87941-55-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Bromo-1-trityl-1H-imidazole is utilized as a building block in organic synthesis for the preparation of various pharmaceuticals and functional materials. Its unique structure and reactivity contribute to the development of new compounds with potential applications in different industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Bromo-1-trityl-1H-imidazole is employed in the production of imidazoles, which are important due to their diverse biological activities. Imidazoles are known to exhibit properties such as antifungal, antibacterial, and antiviral actions, making them valuable in the development of new drugs.
Used in Research Applications:
Due to its unique structure and reactivity, 4-Bromo-1-trityl-1H-imidazole may have potential applications in research, where it can be used to explore new chemical reactions, synthesis pathways, and the development of novel compounds with specific properties.
Used in Pharmaceutical Industry:
4-Bromo-1-trityl-1H-imidazole is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs with improved efficacy and safety profiles. Its presence in the molecular structure of certain compounds can enhance their biological activity and therapeutic potential.
Used in Functional Materials:
4-Bromo-1-trityl-1H-imidazole is also employed in the creation of functional materials, where its unique properties can be harnessed to develop materials with specific characteristics, such as improved conductivity, stability, or responsiveness to external stimuli. These materials can find applications in various industries, including electronics, sensors, and energy storage.

InChI:InChI=1/C22H17BrN2/c23-21-16-25(17-24-21)22(18-10-4-1-5-11-18,19-12-6-2-7-13-19)20-14-8-3-9-15-20/h1-17H

Upstream product

• 2302-25-2 4-bromo-1 H-imidazole 
• 76-83-5 trityl chloride 
• 15469-97-3 N-tritylimidazole 

Downstream Products

• 76-84-6 triphenylmethyl alcohol 
• 121816-84-0 4-bromo-2-nitro-1H-imidazole 
• 121816-85-1 4,5'-Dibromo-2'-nitro-1H,3'H-[2,4']biimidazolyl 
• 121816-83-9 4-bromo-2-methyl-1-tritylimidazole 
• 23593-68-2 2-methyl-1-tritylimidazole 
• 725233-19-2 3-(1-trityl-1H-imidazol-4-yl)phenylamine 
• 1311369-80-8 1-oxo-N-[3-(1-trityl-1H-imidazol-4-yl)phenyl]-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indole-8-carboxamide 
• 1311569-36-4 1-oxo-N-[3-(1-trityl-1H-imidazol-4-yl)phenyl]-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]benzimidazole-8-carboxamide 
• 1311569-38-6 6-oxo-N-[3-(1-trityl-1H-imidazol-4-yl)phenyl]-7,8,9,10-tetrahydro-6H-pyrido[3',2':4,5]pyrrolo[1,2-a][1,4]diazepine-2-carboxamide 
• 1380248-42-9 N-(1-trityl-1H-imidazol-4-yl)nicotinamide 
• 1033822-94-4 N-(1-trityl-1H-imidazol-4-yl)benzamide 
• 197913-15-8 4-amino-1-triphenylmethylimidazole 
• 1402838-08-7 2-[1-(triphenylmethyl)-1H-imidazol-4-yl]benzaldehyde 

Relevant articles and documents

INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS

The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.

A deuterated of the IDO inhibitor and its preparation and use (by machine translation)

The invention provides a deuterated of the IDO inhibitor and its preparation and use, as shown in formula I provide compound or its crystalline form, a pharmaceutically acceptable salt, hydrate or solvate. The preparation of the compound or its crystalline form, a pharmaceutically acceptable salt, hydrate or solvate, can be regarded as the IDO inhibitor, can be used for the treatment of IDO related diseases, in particular cancer, viral infection, depression, neurodegenerative disease, trauma, age-related cataract, organ transplant rejection and autoimmune diseases. (by machine translation)

Synthesis, Biological Evaluation, and Molecular Modeling of 1 -Benzyl-1H-imidazoles as Selective Inhibitors of Aldosterone Synthase (CYP11B2)

Reducing aldosterone action is beneficial in various major diseases such as heart failure. Currently, this is achieved, with mineralocorticoid, receptor antagonists, however, aldosterone synthase (CYP 11B2) inhibitors may offer a promising alternative. In this study, we used three-dimensional modeling of CYP11B2 to model, the binding modes of the natural substrate 18-hydroxycorticosterone and the recently published CYP11B2 inhibitor R-fadrozole as a rational guide to design 44 structurally simple and achiral 1-benzyl-1H-imidazoles. Their syntheses, in vitro inhibitor potencies, and in silico docking are described. Some promising CYP11B2 inhibitors were identified, with our novel lead, MOERAS 115 (4-((5-phenyl-1H-imidazol-1-yl)methyl) benzonitrile) displaying an IC50 for CYP11B2 of 1.7 nM, and a CYP11B2 (versus CYP11B1) selectivity of 16.5, comparable to R-fadrozole (IC 50 for CYP11B26.0 nM, selectivity 19.8). Molecular docking of the inhibitors in the models enabled us to generate posthoc hypotheses on their binding modes, providing a valuable basis for future studies and further design of CYP11B2 inhibitors.

N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors

The invention relates to the use of a N-benzyl 5-substituted imidazole derivative having the general formula I wherein R is (C1-3)alkyl, (C1-3)alkyloxy, halogen, nitro or cyano; R1 is (C1-6)alkyl, optionally substituted with OH, (C1-3)alkyloxy, (C1-3)alkylcarbonyloxy, (C1-3)alkyloxycarbonyl or halogen, or (C1-3)alkyloxycarbonyl; or R1 is phenyl, optionally substituted with 1-3 substituents independently selected from (C1-3)alkyl, (C1-3)alkyloxy, hydroxylmethyl and halogen; or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disorder or disease in a subject mediated by aldosterone synthase or responsive to inhibition of aldosterone synthase.

Synthesis and Reactions of Brominated 2-Nitroimidazoles

Various approaches to the synthesis of the hitherto-unknown 4(5)-bromo-2-nitroimidazole (5) are reported.Direct bromination of 2-nitroimidazole with N-bromosuccinimide gave the unreported 4,5-dibromo-2-nitroimidazole (10) in quantitative yield, but this could be selectively debrominated to give compound (5).While 1-methyl-2-nitroimidazole readily gave 4-bromo-1-methyl-2-nitroimidazole (15) on bromination, this could not be demethylated to give (5), and bromination of various other N-protected 2-nitroimidazoles was also unsuccessful.Lithiation of 4-bromo-1-tritylimidazole (21) followed by quenching with propyl nitrate gave (after detritylation and methylation) a mixture of a dimer (28) and compound (15), indicating that the desired product (5) is produced in this reaction although it can only be isolated in derivatized form.The proposed route for formation of the dimer suggests a general reaction between 1-alkyl-4-bromo-2-nitroimidazoles and strong C- and N-nucleophiles, resulting in substitution at the 5-position.